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Objectives: Infections caused by the rapidly growing mycobacterium (RGM) Mycobacterium abscessus are notori-
ously difficult to treat due to the innate resistance of M. abscessus to most clinically available antimicrobials.
Aminoglycoside antibiotics (AGA) are a cornerstone of antimicrobial chemotherapy against M. abscessus infec-
tions, although little is known about intrinsic drug resistance mechanisms. We investigated the role of chromo-
somally encoded putative aminoglycoside-modifying enzymes (AME) in AGA susceptibility in M. abscessus.
Methods: Clinical isolates of M. abscessus were tested for susceptibility to a series of AGA with different substi-
tuents at positions 2′, 3′ and 4′ of ring 1 in MIC assays. Cell-free extracts of M. abscessus type strain ATCC 19977
and Mycobacterium smegmatis strains SZ380 [aac(2′)-Id+], EP10 [aac(2′)-Id2] and SZ461 [aac(2′)-Id+, rrs
A1408G] were investigated for AGA acetylation activity using thin-layer chromatography (TLC). Cell-free ribosome
translation assays were performed to directly study drug–target interaction.
Results: Cell-free translation assays demonstrated that ribosomes of M. abscessus and M. smegmatis show com-
parable susceptibility to all tested AGA. MIC assays for M. abscessus and M. smegmatis, however, consistently
showed the lowest MIC values for 2′-hydroxy-AGA as compared with 2′-amino-AGA, indicating that an aminogly-
coside-2′-acetyltransferase, Aac(2′), contributes to innate AGA susceptibility. TLC experiments confirmed enzym-
atic activity consistent with Aac(2′). Using M. smegmatis as a model for RGM, acetyltransferase activity was
shown to be up-regulated in response to AGA-induced inhibition of protein synthesis.
Conclusions: Our findings point to AME as important determinants of AGA susceptibility in M. abscessus.
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Introduction
Mycobacterium abscessus is a rapidly growing mycobacterium
(RGM) recognized as an important emerging human pathogen.
M. abscessus causes serious lung infections in patients with chronic
pulmonary diseases, e.g. cystic fibrosis or bronchiectasis,1–3 and is
also associated with infections following surgical interventions4 or
tattooing.5 M. abscessus sensu lato can be subdivided into three
subtaxa, M. abscessus subsp. abscessus, M. abscessus subsp. bolletii
and M. abscessus subsp. massiliense. Identification on a subspecies
level is based on DNA sequences of rpoB and additional genes,
including erm(41), which encodes a 23S rRNA methylase conferring
resistance to macrolides.6 – 8 However, the taxonomy of the
M. abscessus complex is the subject of an ongoing debate.9
M. abscessus sensu lato shows innate antimicrobial resistance
to all major antituberculous drugs in addition to resistance to
broad-spectrum antibiotics such as b-lactams and tetracy-
clines.10 In consequence, infections with M. abscessus respond
poorly to antibiotic chemotherapy.1,11 While no standard treat-
ment recommendations have yet been established, current
guidelines propose administration of an aminoglycoside, prefer-
ably amikacin, and a macrolide, e.g. clarithromycin or azithromy-
cin, in combination with additional compounds, e.g. imipenem,
cefoxitin, linezolid, tigecycline and/or fluoroquinolones, for
M. abscessus pulmonary disease.12 In addition, surgery may be
required to reduce the bacterial load at the site of infection.11,12
Aminoglycoside antibiotics (AGA) form a group of hydrophilic
molecules, consisting of a characteristic, central aminocyclitol
linked to one or more amino sugars by pseudoglycosidic bonds.13
Originally isolated from Streptomyces spp., this class of compounds
has been a major therapeutic component for mycobacterial dis-
eases since the recognition of the activity of streptomycin against
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Mycobacterium tuberculosis.14 In clinically used AGA, the central
2-deoxystreptamine ring is disubstituted at positions 4 and 6 to
result in the 4,6-disubstituted 2-deoxystreptamine antibiotics
(Figure S1, available as Supplementary data at JAC Online). The tar-
get of AGA is the decoding A-site in the bacterial ribosome. AGA are
bactericidal against most bacterial species.13,15 More recently, it was
demonstrated that a chromosomal aminoglycoside-modifying
enzyme (AME) abolishes bactericidal activity of AGA with deletion
of the corresponding gene conferring bactericidal activity to AGA.16
Resistance to AGA is conferred by several mechanisms: drug
modification, target mutation or alteration, reduced uptake and/or
increased efflux.13 Chemical synthesis efforts have focused on
AGA both with a view to confer protection against AME and to
reduce unwanted toxic side effects.17 – 19 In bacterial organisms
that carry a single copy of the 16S rRNA (rrs) gene, e.g. M. absces-
sus and the closely related Mycobacterium chelonae, point muta-
tions in rrs, particularly at 16S rRNA position A1408 (Escherichia
coli numbering), confer high-level resistance (MICs .1000 mg/L)
to all 2-deoxystreptamines, including amikacin, tobramycin,
gentamicin, dibekacin, kanamycin A and kanamycin B.20 – 24 In
addition, AGA resistance can be conferred by target alteration
via rRNA methylases.25,26 Three classes of AME13 have been
described: (i) AGA acetyltransferases catalyse the acetyl-CoA-
dependent N-acetylation of an amino group; (ii) AGA phospho-
transferases transfer the g-phosphoryl group of ATP to a hydroxyl
substituent; and (iii) AGA adenylyltransferases catalyse the transfer
of an adenylyl group to a hydroxyl substituent. In general, expres-
sion of AME is considered to be constitutive.27 However, studies in
Providencia stuartii,28,29 Serratia marcescens,30 Salmonella enter-
ica31 and Pseudomonas aeruginosa32 indicate that AME expression
can be regulated in response to unfavourable environmental con-
ditions, e.g. exposure to subinhibitory AGA concentrations.
The presence of AME has been reported to show little correlation
with intrinsic AGA resistance in RGM.33–35 To study the role of AME
in the intrinsic AGA resistance of M. abscessus in more detail, we
determined: (i) MICs for a panel of AGA with defined substituents
at positions 2′, 3′ and 4′ of ring 1; (ii) acetyltransferase activity in
cell-free extracts of M. abscessus ATCC 19977 and Mycobacterium
smegmatis strains SZ380 [aac(2′)-Id+], EP10 [aac(2′)-Id2] and
SZ461 [aac(2′)-Id+, rrs A1408G]; and (iii) susceptibility of M. absces-
sus ribosomes to various AGA in cell-free translation assays.
Materials and methods
Strains
Clinical strains of M. abscessus subsp. abscessus (n¼4), M. abscessus
subsp. bolletii (n¼4), M. abscessus subsp. massiliense (n¼3) and M. chelo-
nae (n¼5) were isolated from patient specimens. The term ‘M. abscessus
subsp. massiliense’ is used throughout this paper to refer to strains carry-
ing distinct deletions within the erm(41) gene.6,7 M. smegmatis SZ38036 is
a genetically constructed, single rDNA-allelic derivative of M. smegmatis
mc2 155.37 M. smegmatis SZ461 is a derivative of M. smegmatis SZ380
with a 16S rDNA mutation A1408G, conferring high-level resistance to
all 2-deoxystreptamine AGA.23 M. smegmatis EP10 was derived from
M. smegmatis mc2 155 by insertional inactivation of the aac(2′)-Id gene
(GenBank accession number U72743) using an aph(3′) cassette.38
Antibiotic susceptibility testing
Antibiotic susceptibility testing was performed based on CLSI document
M24-A2.39 Amikacin, tobramycin, gentamicin, kanamycin A, kanamycin B
(Sigma-Aldrich, Buchs, Switzerland) and dibekacin (Anawa, Wangen,
Switzerland) were dissolved in sterile water, filter sterilized, aliquotted
into stock solutions of 5 g/L and stored at –808C. Working solutions
were prepared by diluting aliquots of the respective stock solutions in
cation-adjusted Mueller–Hinton broth (CAMHB; Becton Dickinson,
Allschwil, Switzerland) at pH 7.4. Two-fold serial dilutions of the working
solutions were prepared in CAMHB using sterile 96-well microtitre plates
(Greiner Bio-One, St Gallen, Switzerland). In all tests, a growth control with-
out antibiotic and a negative control containing only CAMHB were
included. All antimicrobial solutions were thawed once and leftovers
were discarded after use. For inoculum preparation, colonies were taken
from fresh cultures grown on LB agar using sterile cotton swabs and sus-
pended into glass vials containing 2 mL of sterile saline. Bacterial suspen-
sions were adjusted to a turbidity equivalent to or greater than that of a
0.5 McFarland standard and diluted in CAMHB to generate a final inoculum
suspension of 1–5×105 cfu/mL. Each inoculum suspension was checked
for purity and correct concentration of viable cells by obtaining cfu counts
of suitable dilutions plated on LB agar. After inoculation, microdilution
plates were covered with adhesive seals and incubated at 378C. Growth
was assessed by visual inspection of the microtitre plates after 3, 7 and
12 days of incubation.
Thin-layer chromatography (TLC)
For preparation of cell extracts, bacteria were grown to log phase in
CAMHB. For preincubation, liquid cultures were exposed to subinhibitory
concentrations of tobramycin (1/4 MIC) for 84 h before cell pellets were
harvested, washed twice in drug-free medium and disrupted using the
OmniLyse HL cell lysis kit (Claremont Bio Solutions, Upland, CA, USA). Cell
lysates were centrifuged at 10000 g for 30 min at 48C. The supernatant
was passed through filter paper to remove residual lipids and subse-
quently centrifuged at 22000 g for 40 min at 48C to obtain cell extracts.
Total protein concentration was determined using a bicinchoninic acid
assay (Micro BCA Protein Assay, Thermo Fisher Scientific, Reinach,
Switzerland). Phosphate-buffered acetylation reactions (pH 7.0, total vol-
ume 50 mL) containing cell extract (standardized to 30 mg of total protein),
acetyl-coenzyme A (Sigma-Aldrich; final concentration 4 mM) and one
AGA per reaction (final concentration 500 mg/L) were incubated for 16 h
at 378C. For each experiment, a control reaction containing water instead
of cell extract was incubated in parallel. A 20 mL aliquot of the incubated
reaction mixtures was transferred to a silica gel 60 TLC plate (Merck,
Darmstadt, Germany). For normalization, 10 mL of the respective antibiotic
stock solution (1 g/L) was spotted on every TLC plate. A 5% KH2PO4 solu-
tion was used as the mobile phase. Following separation, TLC plates were
air-dried overnight and stained by spraying with ninhydrin solution (5 g/L
acetone). After staining, TLC plates were incubated at 608C for 20 min and
digitalized; spot intensities were quantified using ImageJ software (http://
rsbweb.nih.gov/ij/).
Isolation of bacterial ribosomes and cell-free luciferase
translation assays
Ribosomes and ribosome-free S100 cell extracts were purified from
bacterial cell pellets as described previously using sucrose gradient (10%–
40%, w/v) centrifugation.17 Concentration of 70S ribosomes was deter-
mined by absorption measurements using a standard value of 23 pmol
ribosomes per A260 unit. Firefly luciferase (F-luc) mRNA was produced
in vitro using T7 RNA polymerase (Thermo Scientific Fermentas, Reinach,
Switzerland) on templates of modified plasmid pGL4.14 (Promega,
Mannheim, Germany).17 A typical translation reaction with a total volume
of 30 mL contained 0.25 mM 70S ribosomes, 4 mg of F-luc mRNA, 40% (v/v)
of ribosome-free S100 extract, 200 mM amino acid mixture, 24 U of RNAse
inhibitor (Ribo Lock, Thermo Scientific Fermentas), 0.4 g/L total E. coli tRNA
and 12 mL of commercial S30 Premix without amino acids (Promega).
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After addition of serially diluted AGA, the reaction mixture was incubated
at 378C for 35 min and subsequently placed on ice. F-luc activity was
quantified using the Luciferase Reporter Assay System (Promega).
Luminescence was measured using a luminometer (FLx800; Bio-Tek
Instruments, Luzern, Switzerland). IC50 values represent the AGA concen-
trations that inhibit F-luc activity by 50%.
Statistical analysis
Statistical analysis was performed using IBM SPSS statistics version 20
(IBM, Armonk, USA) and Microsoft Excel (Microsoft, Redmont, USA).
Student’s t-test was used where applicable. The level of significance was
set at P values of ,0.05.
Results
Determination of AGA MICs
MICs were determined for a range of chemically well-defined
compounds (tobramycin, kanamycin B, amikacin and kanamycin A;
see Figure S1 for chemical structures) using clinical strains of
M. abscessus subsp. abscessus, M. abscessus subsp. bolletii and
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Figure 1. Average MIC ratios of selected aminoglycosides for clinical strains of RGM and M. smegmatis strain SZ380. (a) M. abscessus subsp. abscessus
(four isolates). (b) M. abscessus subsp. bolletii (four isolates). (c) M. abscessus subsp. massiliense (three isolates). (d) M. smegmatis strain SZ380
(measured in triplicate). (e) M. chelonae (five isolates). MICs were normalized to the compound showing the lowest MIC (kanamycin A for
M. abscessus and M. smegmatis, and tobramycin for M. chelonae). Absolute MICs of kanamycin A were: M. abscessus subsp. abscessus, one isolate
1 mg/L, two isolates 8 mg/L and one isolate 16 mg/L; M. abscessus subsp. bolletii, all isolates 8 mg/L; M. abscessus subsp. massiliense, one isolate
4 mg/L and two isolates 8 mg/L; and M. smegmatis, 0.5 mg/L. The absolute MIC of tobramycin for M. chelonae was 16 mg/L for all isolates. Error
bars:+1 SD. TOB, tobramycin; KAN B, kanamycin B; DIB, dibekacin; AMK, amikacin; KAN A, kanamycin A.
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M. abscessus subsp. massiliense (Figure 1a– c). M. smegmatis
strain SZ380 and M. chelonae were used as comparators
(Figure 1d and e). In all subspecies of the M. abscessus complex,
MICs of amikacin and kanamycin A were significantly lower than
those of tobramycin, kanamycin B and dibekacin (P≤0.05). A single
structural feature distinguishes both amikacin and kanamycin A
from tobramycin, kanamycin B and dibekacin, i.e. a hydroxyl
group instead of an amino group at the 2′-position (Figure S1).
The MIC results of M. abscessus complex suggest the presence
of a functional Aac(2′). In contrast to M. abscessus, M. chelonae
showed the lowest MICs for compounds with a 3′-deoxy configur-
ation (tobramycin and dibekacin) (P≤0.01), consistent with the
presence of an Aph(3′) in this species.27
Analysis of aminoglycoside acetylation activity in
M. abscessus and M. smegmatis
AGA acetylation at the 2′ position was first investigated in cell
extracts of M. abscessus ATCC 19977 using TLC. Control reactions,
in which cell extracts were replaced by sterile water, were per-
formed in parallel (see Figure 2). The 2′-amino-AGA kanamycin B
and the 2′-hydroxy-AGA kanamycin A were studied for modifica-
tions. Two well-separated spots were observed for kanamycin B
when incubated with cell extract of M. abscessus ATCC 19977.
One spot corresponds to the unmodified compound while the
other represents the acetylated compound. The control reaction
only showed the unmodified compound. For kanamycin A, incuba-
tion with M. abscessus cell extract only showed a single spot,
which corresponded to the unmodified compound in the control
reaction. These data corroborate the MIC results and demonstrate
the presence of a functionally active 2′-acetyltransferase, Aac(2′),
in cell extracts of M. abscessus ATCC 19977.
Cell extracts ofM. smegmatis SZ380 andM. smegmatis EP10, with
a disrupted aac(2′)-Id gene, were used in combination with different
2′-amino-AGA (kanamycin B and tobramycin) and 2′-hydroxy-AGA
(kanamycin A and amikacin). Similar to M. abscessus, the
2′-amino-AGA showed spots representing acetylation in M. smeg-
matis SZ380, but not in the aac(2′) knockout strain M. smegmatis
EP10. In contrast, the 2′-hydroxy-AGA showed only a single spot cor-
responding to the unmodified compound in both M. smegmatis
SZ380 and M. smegmatis EP10 (Figure 3a).
Regulation of Aac(2) activity
M. abscessus is poorly, if at all, amenable to genetic manipu-
lation.40,41 We thus used the closely related rapidly growing
M. smegmatis (for which genetic manipulation protocols are well
established)20 as a model to further investigate the role of Aac(2′)
enzymes in the activity of substrate and non-substrate AGA. In
these experiments we wanted to study the regulation of Aac(2′)
expression. In particular, we wanted to address the question of
whether these enzymes are induced by treatment with AGA. To
investigate whether acetylation activity is up-regulated in response
to AGA exposure, cell extracts of M. smegmatis SZ380 [aac(2′)-Id+]
and M. smegmatis EP10 [aac(2′)-Id2], which had been preincubated
with subinhibitory concentrations of tobramycin for 0 and 84 h prior
to cell extract preparation, were used in TLC experiments (Figure 3b).
For M. smegmatis SZ380, which had been preincubated with tobra-
mycin, spots indicative of acetylated AGAwere found to be increased
in cell extracts by 1.7-fold when using tobramycin as a substrate
and by 2.8-fold when using gentamicin as a substrate for modifica-
tion. As expected, no acetylation activity was observed using cell
extracts of the aac(2′) knockout M. smegmatis EP10 irrespective of
preincubation.
Next we addressed the mechanism that induces Aac(2′)
expression following treatment with AGA. In principle, two possi-
bilities exist: induction of Aac(2′) as per the chemical nature of the
compound, or induction of Aac(2′) expression as per the drugs’
effect on the bacterial ribosome. To differentiate between these
two possible mechanisms we used M. smegmatis SZ461, a strain
carrying an A1408G mutation in the 16S rRNA. This mutation con-
fers high-level resistance to AGA with MIC levels .128 mg/L and
abolishes the compounds’ inhibitory activity against the bacterial
ribosome.23 The effect of the 16S rRNA A1408G resistance muta-
tion on regulation of aac(2′)-Id expression was studied using cell
extracts of preincubated and non-preincubated M. smegmatis
strains SZ380 [aac(2′)-Id+, rrs WT] and SZ461 [aac(2′)-Id+, rrs
A1408G] (Figure 3c). The basal acetylation activity of Aac(2′)-Id
substrates using cell extracts of non-preincubated strain SZ461
was comparable to that of M. smegmatis SZ380 (rrs WT). In con-
trast, no increase in acetylation activity towards 2′-amino-AGA
was observed for cell extracts of strain SZ461 preincubated with
tobramycin. This finding indicates that up-regulation of AME
expression is conferred by drug-mediated ribosomal inhibition
and not triggered by the compound itself.
Susceptibility of M. abscessus ribosomes to
aminoglycosides
Next, we studied the susceptibility to different AGA directly at the
drug target level using cell-free translation assays. Purified ribo-
somes and ribosome-free S100 extracts were prepared from
Compound KAN B KAN A KAN AKAN B
Cell extract +
+
–
–
+
+
–
–Water control
Figure 2. Aminoglycoside modification by M. abscessus cell extracts.
Aminoglycoside acetylation was studied using TLC with ninhydrin
staining. Shown is a representative example using cell-free extracts
prepared from a liquid culture of M. abscessus ATCC 19977 incubated
with acetyl-CoA and kanamycin B (2′-amino) or kanamycin A
(2′-hydroxy). Acetylation reactions containing cell extract, acetyl-CoA
and antibiotic were incubated for 16 h before they were transferred to
TLC membranes. Control reactions including sterile water instead of cell
extract are also shown. The spot indicative of acetylated kanamycin B is
indicated by an arrow. Baseline is indicated by the horizontal line.
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Figure 3. Aminoglycoside modification by M. smegmatis cell extracts. (a) Acetylation activity towards 2′-hydroxy and 2′-amino AGA was studied using
TLC. Shown is a representative example using kanamycin B and tobramycin (both 2′-amino), kanamycin A and amikacin (both 2′-hydroxy) and cell
extracts prepared from M. smegmatis strains SZ380, EP10 and SZ461. Control reactions without cell extract are also shown. Spots indicative of
acetylated aminoglycosides are indicated by arrows. (b) Aminoglycoside acetyltransferase activity in cell extracts of M. smegmatis SZ380 (WT) and
M. smegmatis EP10 [aac(2′)-Id knockout, WT rrs]. Cell extracts were preincubated with subinhibitory concentrations of tobramycin for 0 and 84 h
prior to cell wall disruption, respectively. Shown are the relative intensities of spots indicative of acetylated aminoglycosides normalized to
M. smegmatis SZ380 without preincubation. (c) Comparison of acetyltransferase activities between cell extracts of M. smegmatis SZ380 (WT) and
M. smegmatis SZ461 [aac(2′)-Id WT, A1408G rrs mutant], which were preincubated in tobramycin for 0 and 84 h prior to cell wall disruption,
respectively. Normalization was performed as in (b). Error bars:+1 SD. *P,0.05.
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clinical isolates of the M. abscessus complex and M. smegmatis
SZ380. IC50 values were determined, i.e. drug concentrations
required to inhibit F-luc mRNA translation by 50%. The results of
these experiments are shown in Table 1. When ribosomes and
S100 extract from M. smegmatis SZ380 were combined, IC50
values of 0.01–0.03 mg/L were determined for all AGA. When
purified ribosomes and S100 extract from M. abscessus were
combined, IC50 values of 0.02 –0.05 mg/L were observed for
amikacin and kanamycin A. However, IC50 values for tobramycin,
kanamycin B and dibekacin were 0.22–0.90 mg/L.
We next assessed whether the elevated IC50 values of tobra-
mycin, kanamycin B and dibekacin in M. abscessus were due to
resistance of M. abscessus ribosomes, e.g. as per ribosomal
methylation, or AME enzymatic activity present in the M. absces-
sus S100 extracts. For this purpose, cross-over experiments were
performed, in which ribosomes from M. abscessus were combined
with S100 extract from M. smegmatis SZ380 and ribosomes from
M. smegmatis SZ380 were combined with S100 extract from
M. abscessus. M. abscessus ribosomes in combination with S100
extract from M. smegmatis resulted in IC50 values for tobramycin,
kanamycin B and dibekacin that were similar to those of amikacin
and kanamycin A (0.01 –0.05 mg/L). In contrast, when S100
extract from M. abscessus was used in combination with M. smeg-
matis ribosomes, IC50 values of 0.81, 1.56 and 0.66 mg/L were
observed for tobramycin, kanamycin B and dibekacin, respectively.
These findings indicate that AGA susceptibility at the drug target
level (the ribosome) is similar for both M. smegmatis and
M. abscessus and that the increased IC50 values for tobramycin,
kanamycin B and dibekacin observed in M. abscessus resulted
from pronounced enzymatic activity [consistent with Aac(2′)] in
the S100 extracts of M. abscessus.
Discussion
The purpose of this study was to investigate the role of AME in AGA
susceptibility of RGM, with special emphasis on M. abscessus. At the
MIC level, the drug susceptibility pattern ofM. abscessuswas similar
to that of M. smegmatis and clearly different from that of the close-
ly related M. chelonae. MICs of the 2′-hydroxy AGA kanamycin A
and amikacin were significantly lower than MICs of the
2′-amino-AGA tobramycin, kanamycin B and dibekacin (Figure 1).
Based on these observations, we hypothesized that a homologue
of Aac(2′), capable of acetylating 2′-amino-2-deoxystreptamines,
contributes to the innate AGA susceptibility of M. abscessus. This
hypothesis is supported by the presence of an aac(2′) homologue
(GenBank accession number MAB_4395) in the M. abscessus
chromosome.42 Indeed, acetylation studies indicated the presence
of a functional Aac(2′) acetyltransferase in M. abscessus (Figure 2).
This finding is of clinical importance as it was recently shown that
expression of AME in RGM can significantly affect both MICs and the
bactericidal activity of AGA.16
Little is known regarding the mechanisms that regulate the
expression of AME. In general, these enzymes are thought to be
expressed constitutively.27 To study the regulation of AME expres-
sion in RGM in more detail, we took advantage of M. smegmatis, as
an aac(2′) knockout mutant was available. Baseline acetylation
activity was abolished in the aac(2′)-Id knockout strain M. smeg-
matis EP10 as compared with M. smegmatis SZ380, indicating
that Aac(2′)-Id is the only aminoglycoside-acetylating enzyme
present in M. smegmatis (Figure 3b). M. smegmatis SZ380 showed
increased enzymatic activity when preincubated with subinhibi-
tory AGA concentrations before preparation of cell extracts
(Figure 3b). However, no such increase in acetylation activity
was observed in M. smegmatis SZ461, which carries the AGA
resistance mutation A1408G in the 16S rRNA gene (Figure 3c).
This finding indicates that the basal expression of aac(2′)-Id is
constitutive and comparable in rrs WT and rrs A1408G mutant
strains. However, basal Aac(2′)-Id activity is increased upon
exposure to AGA. This AGA-induced increase in AME activity was
only observed in the rrs WT strain, indicating that drug-mediated
inhibition of protein synthesis is required to up-regulate AME
expression.
Our findings in M. smegmatis on drug-induced ‘ribosomal stress’
and up-regulation of genes conferring resistance to compounds
that act on the bacterial ribosome are not without precedent.
Nash et al.6 demonstrated that mRNA transcript levels of
erm(41), which confers macrolide resistance by methylation of pos-
ition A2058 in the 23S rRNA (rrl) gene, increase in response to
macrolide exposure. However, no such increase was observed in
strains carrying a mutated position 2058, which confers resistance
to MLSB antibiotics.
6 In addition, expression of the transcriptional
regulator whiB7 is up-regulated in response to treatment with
the ribosomal inhibitors kanamycin, streptomycin, erythromycin
and tetracycline.43,44 Among the whiB7-dependent transcripts are
the tapmultidrug-efflux transporter, which confers low-level resist-
ance to AGA and tetracyclines,45,46 and the erm(37) ribosomal
Table 1. In vitro inhibition of protein synthesis
Purified ribosomes S100 extract
IC50 (mg/L)
TOB KAN B DIB AMK KAN A
M. smegmatis SZ380 M. smegmatis SZ380 0.01 0.02 0.02 0.02 0.03
M. abscessus subsp. abscessus 500042 M. abscessus subsp. abscessus 500042 0.22 0.90 0.82 0.03 0.02
M. abscessus subsp. massiliense 186139 M. abscessus subsp. massiliense 186139 0.26 0.56 0.32 0.05 0.04
M. abscessus subsp. abscessus 500042 M. smegmatis SZ380 0.01 0.03 0.03 0.05 0.05
M. smegmatis SZ380 M. abscessus subsp. abscessus 500042 0.81 1.56 0.66 0.11 0.09
TOB, tobramycin; KAN B, kanamycin B; DIB, dibekacin; AMK, amikacin; KAN A, kanamycin A.
Translation inhibition was measured by analysis of luciferase activity following translation of F-luc template mRNA. IC50 values represent the drug con-
centrations at which luciferase activity was reduced by 50%. Shown are the results for combinations of ribosomes and S100 preparations of two clinical
M. abscessus complex isolates and for M. smegmatis strain SZ380 (all rrs WT).
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methyltransferase, conferring macrolide resistance.47 Most inter-
estingly, in E. coli, formation of biofilms has been identified as a
stress response, which is induced upon exposure to various transla-
tion inhibitors. This stress response is mediated via a regulatory
mechanism involving the bacterial signalling molecules guanosine-
bis 3′,5′(diphosphate) and bis-(3′-5′)-cyclic di-GMP.48
In conclusion, this study provides evidence that the innate AGA
susceptibility of M. abscessus is determined by a functional Aac(2′)
acetyltransferase. Our findings also indicate that regulation of chro-
mosomally encoded AME in RGM involves constitutive and inducible
elements. The inducible regulation appears to be mediated via the
effect of AGA on the bacterial ribosome (‘ribosomal stress’). It most
likely involves a more general and complex signal transduction
pathway consistent with an adaptive response.
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